Martindale Pharma study shows benefits of opioid substitution therapy Espranor

Martindale Pharma has announced the findings of a new study showing the benefits of its opioid substitution therapy Espranor.

Data from a phase II study of the drug has been published in the journal European Addiction Research, showing how the rapidly dissolving oral lyophilisate formulation of buprenorphine can be effective in helping those battling opioid addictions.

When compared with current hard sublingual tablets, Espranor was shown to dissolve quickly, with no increased safety concerns or demonstrable difference in efficacy.

Approximately 50 percent of patients drop out of both buprenorphine and methadone maintenance treatment within six months, with a number of limitations hampering the effectiveness of sublingual buprenorphine, including the length of time it takes to dissolve and the close supervision it requires.

As such, rapidly-dissolving formulations of buprenorphine may minimise supervision times and the opportunity for the diversion of medicines for misuse, meaning Espranor represents the first major advance in opioid substitution therapy for a decade.

Dr Shelagh Baillie, medical director of Martindale Pharma, said: "This data demonstrates that using this rapidly-dissolving formulation of buprenorphine may offer practical benefits without compromising safety or efficacy."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.